Skip to content

Accounts Payable at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$4.23B+5.8%
Gilead Sciences logo
Gilead SciencesGILD
$645M-12.5%
Kyverna Therapeutics, Inc. logo
Kyverna Therapeutics, Inc.KYTX
$11.6M+37.0%
Allogene Therapeutics logo
Allogene TherapeuticsALLO
$4.93M-2.5%
Immix Biopharma, Inc. logo
Immix Biopharma, Inc.IMMX
$4.73M-17.6%
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
$2.51M-26.2%

Other financials

Income statement

See full
Revenue-
Operating income-$24.4M-10.2%
Net income-$23.5M-15.8%
EPS (diluted)-$0.95-14.5%

Balance sheet

See full
Cash & equivalents$21.4M-30.6%
Total debt$10.3M-26.7%
Total equity$87.8M-48.0%
Total assets$106.0M-44.6%

Cash flow

See full
Operating cash flow-$21.0M-5.6%
CapEx$242.0K-52.6%
Free cash flow-$21.2M-4.1%

Valuation

See full
Market cap$429.03M+1,015%
Enterprise value$417.88M+1,832%

Profitability

See full
Operating margin-83.9%
Net margin-79.3%

Returns & leverage

See full
Return on equity-67.9%
Debt / equity0.1×0.0×
Current ratio8.2×-5.8×

Where this comes from

Reported directly by Artiva Biotherapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:AccountsPayableCurrent.

The official record: Artiva Biotherapeutics, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Artiva Biotherapeutics, Inc.'s accounts payable.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Artiva Biotherapeutics, Inc.'s accounts payable?
Artiva Biotherapeutics, Inc. (ARTV) reported accounts payable of $2.29M in Q1 2026.
How has Artiva Biotherapeutics, Inc.'s accounts payable changed year-over-year?
Artiva Biotherapeutics, Inc.'s accounts payable increased by 12.3% year-over-year, from $2.04M to $2.29M.
What does accounts payable mean?
Amounts owed to suppliers and vendors for goods and services received but not yet paid. A primary source of short-term trade financing.